ResearcherIndiana University HealthActive in the last 2 years
Rajesh Sardar
Matched on ORCID iD 0000-0001-9680-1301; OpenAlex author ID A5072536092. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 12
2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 2 papers
Papers 4
- Beyond Cys65: Redox Effector Factor-1 CRISPR-Engineered Cys93 and Cys99 Mutants Reveal Cooperative and Secondary Roles of Redox Signaling and Pancreatic Ductal… Co-author DOI 10.1177/15230864261489484↗
- Targeting APE1 endonuclease activity impairs metastasis and enhances genotoxic therapy response in pancreatic cancer. Co-author DOI 10.1186/s13046-026-03705-7↗
- Amplification-Free, High-Throughput Nanoplasmonic Quantification of Circulating MicroRNAs in Unprocessed Plasma Microsamples for Earlier Pancreatic Cancer Dete… Last author DOI 10.1021/acssensors.2c02105↗
- Highly specific plasmonic biosensors for ultrasensitive microRNA detection in plasma from pancreatic cancer patients. Last author DOI 10.1021/nl503220s↗
Closest collaborators
The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Melissa L. Fishel · 3 shared papers, 2023–2026 · strength 0.68
- Paper Beyond Cys65: Redox Effector Factor-1 CRISPR-Engineered Cys93 and Cys99 Mutants Reveal Cooperative and Secondary Roles … DOI 10.1177/15230864261489484↗
- Paper Targeting APE1 endonuclease activity impairs metastasis and enhances genotoxic therapy response in pancreatic cancer. DOI 10.1186/s13046-026-03705-7↗
- Paper Amplification-Free, High-Throughput Nanoplasmonic Quantification of Circulating MicroRNAs in Unprocessed Plasma Microsa… DOI 10.1021/acssensors.2c02105↗
- Mahmut Mijit · 2 shared papers, 2026 · strength 0.51
- Paper Beyond Cys65: Redox Effector Factor-1 CRISPR-Engineered Cys93 and Cys99 Mutants Reveal Cooperative and Secondary Roles … DOI 10.1177/15230864261489484↗
- Paper Targeting APE1 endonuclease activity impairs metastasis and enhances genotoxic therapy response in pancreatic cancer. DOI 10.1186/s13046-026-03705-7↗
- Silpa Gampala · 2 shared papers, 2026 · strength 0.51
- Paper Beyond Cys65: Redox Effector Factor-1 CRISPR-Engineered Cys93 and Cys99 Mutants Reveal Cooperative and Secondary Roles … DOI 10.1177/15230864261489484↗
- Paper Targeting APE1 endonuclease activity impairs metastasis and enhances genotoxic therapy response in pancreatic cancer. DOI 10.1186/s13046-026-03705-7↗
- Eyram K. Kpenu · 2 shared papers, 2026 · strength 0.51
- Paper Beyond Cys65: Redox Effector Factor-1 CRISPR-Engineered Cys93 and Cys99 Mutants Reveal Cooperative and Secondary Roles … DOI 10.1177/15230864261489484↗
- Paper Targeting APE1 endonuclease activity impairs metastasis and enhances genotoxic therapy response in pancreatic cancer. DOI 10.1186/s13046-026-03705-7↗
- Sanya Haiaty · 2 shared papers, 2026 · strength 0.51
- Paper Beyond Cys65: Redox Effector Factor-1 CRISPR-Engineered Cys93 and Cys99 Mutants Reveal Cooperative and Secondary Roles … DOI 10.1177/15230864261489484↗
- Paper Targeting APE1 endonuclease activity impairs metastasis and enhances genotoxic therapy response in pancreatic cancer. DOI 10.1186/s13046-026-03705-7↗
- Mark R. Kelley · 2 shared papers, 2026 · strength 0.51
- Paper Beyond Cys65: Redox Effector Factor-1 CRISPR-Engineered Cys93 and Cys99 Mutants Reveal Cooperative and Secondary Roles … DOI 10.1177/15230864261489484↗
- Paper Targeting APE1 endonuclease activity impairs metastasis and enhances genotoxic therapy response in pancreatic cancer. DOI 10.1186/s13046-026-03705-7↗
- Nayela N. Chowdhury · 1 shared paper, 2023 · strength 0.17
- Adrianna N. Masterson · 1 shared paper, 2023 · strength 0.17
- Michele Yip-Schneider · 1 shared paper, 2023 · strength 0.17
- Christian Max Schmidt · 1 shared paper, 2023 · strength 0.17
- Gayatri K. Joshi · 1 shared paper, 2014 · strength 0.05
- Murray Korc · 1 shared paper, 2014 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.